Cartherics Pty Ltd. has raised over its target of AU$15 million (US$10.3 million) in an oversubscribed private financing round. Funding will support a clinical trial for CTH-401, the company’s lead cell therapy for ovarian cancer, and expand its pipeline to include other diseases.